Drug
tandutinib
tandutinib is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
withdrawn125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
NCT00408902
completedphase_1
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
NCT00379080
completedphase_2
Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
NCT00390468
withdrawnphase_1
A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy
NCT00297921
Clinical Trials (4)
Showing 4 of 4 trials
NCT00408902Phase 2
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
NCT00379080Phase 1
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
NCT00390468Phase 2
Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
NCT00297921Phase 1
A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4